Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal
Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...
Le Lézard5d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday
Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, FNA, ALMS, HEES On Behalf Of Shareholders
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...
Alumis price target lowered to $26 from $32 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...
The Pharma Letter9d
The week in pharma: action, reaction and insight – week to February 7
News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...
12 Health Care Stocks Moving In Friday's Pre-Market Session
This article was generated by Benzinga's automated content engine and reviewed by an editor.